							Τ,		
Please	hma	•	ohie	cion .	-	مhiani ۱	thie	h	
r icase	() pc	•	pius	Sign :	٠.	1 11 12 12 12	uus	~~	_

PTO/SB/08B (08-00)
Approved for use 1-rough 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 6 Sheet

ond to a concount of information	Tutiless it contains a valid Olvid Condot Humber.					
Complete if Known						
Application Number 09/614,389						
Filing Date	7/12/2000					
First Named Inventor	Rasor					
Group Art Unit						
Examiner Name						
Attorney Docket Number	CAPR 1010					

]		Include name of the author (in CADITAL LETTERS) title of the extiste (when appropriate) title of the	<u> </u>				
Examiner Cit. No							
		ANTON F, EUCHNER I, HANDWERKER HO. Psychophysical examination of pain induced by defined CO ₂ pulses applied to the nasal mucosa. Pain 49:53-60, 1992					
		CHA EJ, SEDLOCK D, YAMASHIRO SM. Changes in lung volume and breathing pattern during exercise and CO₂ inhalation in humans. J Appl Physiol 62(4):1544-50, Apr 1987					
		DEXTER SL. Rebreathing aborts migraine attacks. Br Med J (Clin Res Ed) 1982 Jan 30;284(6312):312					
		DIAMOND S, DALESSIO DJ, course directors. The 13th Annual Practicing Physician's Approach to the Difficult Headache Patient. Rancho Mirage, CA. February 15-19, 2000					
		ECHARRI RM, RIVERA T, MATE MA, COBETA I. [Sudden deafness: efficacy of a therapeutic protocol]. [Article in Spanish] Acta Otorrinolaringol Esp 51(6):490-4 Aug-Sep 2000					
		FAISY C, DIEHL JL, GUEROT E, REZGUI N, LABROUSSE J. [Use of the helium-oxygen mixture in pneumology practice]. [Article in French]. Rev Mal Respir 1999 Dec;16(6):1063-73					
		FIERMONTE G, PIERELLI F, PAURI F, COSENTINO FII, SOCCORSI R, GIACOMINI P. Cerebrovascular CO₂ reactivity in migraine with aura and without aura. A transcranial Doppler study. Acta Neurol Scand 92(2):166-9. Aug 1995					
		FISHER HK, HANSEN TA. Site of action of inhaled 6 percent carbon dioxide in the lungs of asthmatic subjects before and after exercise. Am Rev Respir Dis 114(5):861-870, 1976.					
		FISHER HK, HOLTON P, BUXTON R ST J, NADEL JA. Resistance to breathing during exercise-induced asthma attacks. Amer Rev Resp Dis 101:885-896, 1970					
		GILLMAN MA, LICHTIGFELD FJ. Placebo and analgesic nitrous oxide for treatment of the alcohol withdrawal state. Br J Psychiatry 159:672-5, Nov 1991					
N		GLOVSKY MM. Upper airways involvement in bronchial asthma. Cur Opin in Pulm Med 4:54-58, 1998					

Signature Considered A MAN V

*EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation if notific conformance and not considered. Include copy of this form with next communication to applicant. 20

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Examiner

Signature

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number. no persons are required to respond

Substitute for form 1449B/PTO **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

Complete if Known **Application Number** 09/614.389 **Filing Date** 7/12/2000 **First Named Inventor** Rasor **Group Art Unit Examiner Name**

(use as many sheets as necessary) of Sheet 6 2

Attorney Docket Number CAPR 1010

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	2	GROSSER, K.; OELKERS, R.; HUMMEL, T.; GEISSLINGER, G.; BRUNE, K.; KOBAL, G.; L.TSCH, J. Olfactory and trigeminal event-related potentials in migraine. Cephalalgia 2000 8ep;20:621-31	
1		GROSSHANS A, GENSCH H. [CO₂ gas injection – indications and results]. Z Gesamte Inn Med 42(23):667-70, 1987	\
		GUYTON AC, HALL JE. Textbook of Medical Physiology. Ninth Edition, WB Saunders, Philadelphia, 1996, pp. 101, 203-04, 206-07, 454, 487, 515, 520-23, 527-30, 541-44, 572-73, 617-19, 694	
		HOLLMAN G, SHEN G, ZENG L, YNGSDAL-KRENZ R, PERLOFF W, ZIMMERMAN J, STRAUSS R. Helium-oxygen improves Clinical Asthma Scores in children with acute bronchiolitis. Crit Care Med 26(10):1731-6, Oct 1998	
		JOLLIET P, TASSAUX D, THOURET JM, CHEVROLET JC. Beneficial effects of helium- oxygen versus air-oxygen noninvasive pressure support in patients with decompensated chronic obstructive pulmonary disease. Crit Care Med 27(11):2422-9, Nov 1999	
		RODARTE JR, HYATT RE. Effect of acute exposure to CO₂ on lung mechanics in normal man. Resp Physiol 17:135-145, 1973	
		SAQUETON CB, MILLER RB, PORTER VA, MILLA CE, CORNFIELD DN. NO causes perinatal pulmonary vasodilation through K+-channel activation and intracellular Ca2+ release. Am J Physiol 276(6 Pt 1):L925-L932, Jun 1999	
		SCHAEFFER EM, POHLMAN A, MORGAN S, HALL JB. Oxygenation in status asthmaticus improves during ventilation with helium-oxygen. Crit Care Med 27(12):2666-70, Dec 1999	
		SCHUTTAUF F, COBET U, KLEMENZ A, KRAUSE A. [Duplex ultrasound examinations of retinal circulation after inhalation of various mixed respiratory gases.] Opthalmologe 95(4):225-8, Apr 1998	
		SINGH V, WISNIEWSKI A, BRITTON J, TATTERSFIELD A. Effect of yoga breathing exercises (pranayama) on airway reactivity in subjects with asthma. Lancet 335:1381-3, 1990	RE
	/	ΕΡ 18	CF
		STERLING GM, HOLST PE, NADEL JA. Effect of CO₂ and pH on bronchoconstriction caused by serotonin vs. acetylcholine. J. Appl. Physiol. 32(1):39-43, Jan 1972	UJVI
		3700	

*EXAMINER: Initial if reference considered hower or pot citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Date

Considered

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

	PTO/SB/08B (08-0
se type a plus sign (+) inside this box -> +	Approved for use through 10/31/2002. OMB 0651-003
	U. S. Patent and Trademark Office: EPARTMENT OF COMMERCE
the Panerwork Reduction Act of 1995, no persons an	e required to respond to a collection of information unless it a suns a valid OMB control number

Plea

	Cubatikuta	for form 1449l	P/PTO	_	Cor	mplete if Known
ı	•				Application Number	09/64/ 389
	INFO	RMATI	ON DI	SCLOSURE	Filing Date	07/12/2000
16	CTA	TEMEN	TRY	APPLICANT	First Named Inventor	Rasor
	917			AI I LIOMITI	Group Art Unit	
1 %	1	(use as ma	any sheets a	APPLICANT as necessary)	Examiner Name	
氢	neet	3	of	6	Attorney Docket Number	CAPR 1010
.87						

		OTHER PRIOR ART - NON PATENT LITERATU	JRE DOCUME	NTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article item (book, magazine, journal, serial, symposium, catalog, etc.), date, publisher, city and/or country where publis	age(s), volume-is	te), title of the sue number(s),	T²
		JOZEFOWICZ RF. Neurologic manifestations of pulmonary 7(3):605-616, 1989	disease. Neur	rologic Clinics	
		LOEVENHART AS, LORENZ WF, WATERS RM. Cerebral s 92(11):880-883, 1929	timulation. JA	MA	
		LOH E, LANKFORD EB, POLIDORI DJ, DOERING-LUBIT E MA. Cardiovascular effects of inhaled nitric oxide in a canine Ann Thorac Surg 67(5):1380-5, May 1999			
,		MARCUSSEN RM, WOLFF HG. Studies on headache: 1. Ef oxygen mixtures given during the pre-headache phase of the analysis of pain mechanisms in headache. Arch Neurol Psyc	e migraine atta	ack. 2. Further	
		MEDUNA LJ ed, <u>Carbon Dioxide Therapy A Neurophysiolog Disorders</u> . Second Edition, LJ Charles C. Thomas publisher,			
		MEDUNA LJ. Pharmaco-dynamic treatment of psychoneuro- Nerv System 8(2), 1947	ses (a prelimir	nary report). Dis	
		NATIONAL HEADACHE FOUNDATION. A Patient's Guide to Treatment. Chicago, IL, Aug 1996	o Migraine Pr	evention &	
		NAVARRA P, DELLO RUSSO C, MANCUSO C, PREZIOSI neuromodulators in the control of neuroendocrine stress axis 2000;917:638-46			
		NIELSEN TM, PEDERSEN OF. The effect of CO₂ on periphe Scand 98(2):192-9, Oct 1976	eral airways. A	Acta Physiol	
·		PAGANO D, TOWNEND JN, HORTON R, SMITH C, CLUTT RS. A comparison of inhaled nitric oxide with intravenous va of pulmonary haemodynamics prior to cardiac transplantation 10(12):1120-6, 1996	sodilators in th	he assessment	
	2	REAM RS, HAUVER JF, LYNCH RE, KOUNTZMAN B, GAL inhaled nitric oxide improves the oxygenation and ventilation acute, hypoxemic respiratory failure. Crit Care Med 27(5):98	of infants and	d children with	
///			Ī.	.(ω	_
			D-4	ΔĜ	
Examin			Date	(LD) 100/11:	,
Signatu	re I		Considered	FYLWOX	٧.

ether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not *EXAMINER: Initial if reference considered, whether or not citation is in conconsidered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Sheet

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

6

Complete if Known **Application Number** 09/614,389 Filing Date <u>7/12/2000</u> First Named Inventor **Group Art Unit Examiner Name** Attorney Docket Number CAPR1010

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
aminer tials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		WILMOTH DF, CARPENTER RM. Preventing complications of mechanical ventilation: permissive hypercapnia. AACN Clin Issues 7(4):473-81, Nov 1996.	
		TANG A, RAYNER M, NADEL J. Effect of CO₂ on serotonin-induced contraction of isolated smooth muscle. Clinical Research 20:243, 1972	
/ /		CHATKIN, J M, ET AL., Nasal Nitric Oxide is Independent of Nasal Cavity Volume, Am J. Rhinol, 1999, 13(3): 179-84	
		SILKOFF, P E, ET AL., Nasal Nitric Oxide: A comparison of Measurement Techniques, Am J. Rhinol, 1999 13(3) 169-78	
•			
		ECHNO	Z1)
		100 / C	E0E
		2001 NTLR	VED.
		3	\square
			\mathcal{H}
_			

*EXAMINER: Initial if reference considered, whether or not estation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with first comparisation to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

6 of Sheet

ond to a concessor of information unless it contains a valid divis control from sec.								
Complete if Known								
Application Number	Application Number 09/614.389							
Filing Date	7/12/2000							
First Named Inventor	Rasor							
Group Art Unit								
Examiner Name								
Attorney Docket Number	CARR 1010							

				U.S. PATENT DOC	JMENTS	
Examiner Initials	Cite No. ¹	U.S. Patent I Number	Cocument Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		1,288,850		Easly	12/24/1918	
		1,449,047		Johnson	03/20/1923	
		2,651,303		Johnson, et al.	09/08/1953	_
		2,860,634		Duncan, et al.	11/18/1958	
		3,513,843		Exler	05/26/1970	
		3,776,227		Pitesky, et al.	12/04/1973	
		3,870,072		Lindmann	03/11/1975	
		3,934,585		Maurice	01/27/1976	
		4,067,499		Cohen	01/10/1978	
		4,137,914		Wetterlin	02/06/1979	
		4,554,916		Watt	11/26/1985	
		5,262,180		Orlando, et al.	11/16/1993	
		5,431,155		Marelli	07/11/1995	
		5,485,827		Zapol	01/23/1996	
		5,570,683		Zapol	11/05/1996	
	,	5,807,357		Kang	09/15/1998	
		5,938,590		Elliott	08/17/1999	_
		5,941,241		Weinstein, et al.	08/24/1999	
	7	5,983,891		Fukunaga	11/16/1999	
	2	5,993,428		Hardge	11/30/1999	

				FORE	IGN PATENT DOCUMENT	rs	
xaminer nitials*	Cite No.1	Office ³	Foreign Patent Do	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Z_\\	O 99	/29249		Cardia Innovation AB	06/17/1999	
	_						
							CH NO T
							हुँ हैं भी
]	ER OF
Exami Signat						Date 2	2 Ju/02

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Signature

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to response

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 6

ond to a conscion of knormation priess it contains a valid often control number.							
Co	emplete if Known						
Application Number	09/614.389						
Filing Date	7/12/2000						
First Named Inventor	Rasor						
Group Art Unit							
Examiner Name							
Attorney Docket Number	CAPR 1010						

				U.S. PATENT DOC	JMENTS	
Examiner Initials	Cite No.1	U.S. Patent Number	Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	,	4,188,946		Watson, et al.	02/19/1980	
	2	3,974,830		LaVerne	08/17/1976	
6						
		$\overline{}$	++			
			\rightarrow			
			+			·
				•		

				FORE	IGN PATENT DOCUMENT	rs		
Examiner Initials	Cite No.1	Foreign Patent Document Kind Code ³ Office ³ Number ⁴ (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6	
		wo	00/57851		Pozen Inc.	10/05/2000)3.	
6	Ļ	DE	19548652 A1		Steinfatt	10/16/1997	H 23	
1/2		DE	4319612 A1	1 1	Beyer, et al.	12/15/1994	é s	5
		wo	00/51672		Djupseland	09/08/2000		1
\blacksquare		\Box					<u> </u>	Ш
	/						0 Z	Ξ,
								-
						· ·		Ĺ
		1				į.		
				•	-	[.	ŏ	-
Exami	inor I	_			In	Date 1		

tion is in conformance with MPEP 609. Draw line through citation if not in conformance and not *EXAMINER: Initial if reference considered, whether it not citation is in conconsidered. Include copy of this form with next communication to applicant.

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.